{
    "clinical_study": {
        "@rank": "134417", 
        "arm_group": [
            {
                "arm_group_label": "13C-labeled acetate", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "13C-labeled propionate", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "13C-labeled butyrate", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Inulin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the bioavailability of acetate, propionate and\n      butyrate in healthy humans using a stable isotope technology.\n\n      In addition the level of acetate, propionate and butyrate production from inulin will be\n      determined using the principle of isotope dilution."
        }, 
        "brief_title": "Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans", 
        "condition": "Short Chain Fatty Acids Bioavailability", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers\n\n          -  Regular dietary pattern (3 meals/day)\n\n          -  Age: 18-65y\n\n          -  BMI: 18,5-27 kg/m2\n\n        Exclusion Criteria:\n\n          -  Intake of antibiotics 1 month prior to the study\n\n          -  Abdominal surgery in the past, with the exception of appendectomy\n\n          -  Intake of medication influencing the gastro-intestinal system 14 days prior to the\n             study\n\n          -  In treatment at a dietician\n\n          -  Intake of pre- and/or probiotics\n\n          -  Exposure to radioactivity 1 year prior to the study\n\n          -  Serious chronic disease of the gastrointestinal tract\n\n          -  Use of medication that affects the gastro-intestinal tract during the last 2 weeks\n             prior to the study\n\n          -  Pregnancy, pregnancy desire or lactation\n\n          -  Blood donation during the last 3 months prior to the study\n\n          -  Diabetes (type 1 or 2)\n\n          -  Aberrant hemoglobin level (Hb) in blood. Normal between 14.0 and 18.0 g/dL for men\n             and between 12.0 and 16.0 g/dL for women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757379", 
            "org_study_id": "ML5768"
        }, 
        "intervention": [
            {
                "arm_group_label": "13C-labeled acetate", 
                "description": "400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)", 
                "intervention_name": "13C-labeled Acetate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "13C-labeled propionate", 
                "description": "340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)", 
                "intervention_name": "13C-labeled propionate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "13C-labeled butyrate", 
                "description": "990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)", 
                "intervention_name": "13C-labeled butyrate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Inulin", 
                "description": "15 g of inulin dissolved in 200 ml of water", 
                "intervention_name": "Inulin", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Short chain fatty acids", 
            "Acetate", 
            "Propionate", 
            "Butyrate", 
            "Bioavailability"
        ], 
        "lastchanged_date": "January 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "state": "Vlaams-Brabant", 
                    "zip": "3000"
                }, 
                "name": "KU Leuven/ UZ Leuven"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "Evaluation of the Bioavailability and Production of Short Chain Fatty Acids in the Colon. A Stable Isotope Study in Healthy Humans.", 
        "overall_official": {
            "affiliation": "KU Leuven", 
            "last_name": "Kristin Verbeke, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Participants performed each 4 test days and they were followed each test day for 12 hours, with sample collections at regular time points. Blood samples were collected every hour during the first 4 hours and afterwards every 20 minutes during 8 hours. Urine samples were collected during 24h in different fractions: 0-4h, 4-8h, 8-12h, 12-24h.", 
            "measure": "Concentrations of the short chain fatty acids (acetate, propionate and butyrate) in plasma and urine samples", 
            "safety_issue": "No", 
            "time_frame": "12 hours each test day and 4 test days/volunteer"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757379"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Katholieke Universiteit Leuven", 
            "investigator_full_name": "Kristin Verbeke", 
            "investigator_title": "Professor K. Verbeke", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Katholieke Universiteit Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Katholieke Universiteit Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}